overpriced and overhyped

PTD has failed to deliver to most shareholders. It is trading at a value much much higher than its true fundamentals.

Let us examine the following :

* It has to fight, in court, several "large" organisations which it claims have breached its patents and which have refused to pay to it royalties as a result.
* It will exhaust substantial monetary resources to achieve the above with no guarantee of success.
* Any further cash needed to be raised will most likely be below the last capital raising price resulting in further dilution.
* Institutions will only stick around for so long before pulling the plug and moving on ( remember when it fell in the 80's price range ). News has only worsened since it traded in that region.

Unless Wednesday's announcement is a very very positive one (ie. they have managed to secure the above disputed royalty payments), then PTD will most likely retrace to below its previous 12 month low.

Good luck to those that continue to play this ailing biotech. There are better opportunities elsewhere in the bio sector.

JBriggs